阳性非小细胞肺癌-话题@MedSci

#阳性非小细胞肺癌#

40篇内容 | 1440人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2045839, encodeId=37c320458396b, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹, objectType=article, longId=111480, objectId=aacf11148072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aacf11148072, replyNumber=0, likeNumber=54, createdTime=2017-09-25, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aacf11148072, moduleTitle=NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aacf11148072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045835, encodeId=00a420458354b, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌, objectType=article, longId=100784, objectId=52ba100e84d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ba100e84d9, replyNumber=0, likeNumber=40, createdTime=2018-04-23, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ba100e84d9, moduleTitle=ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52ba100e84d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045832, encodeId=983520458324b, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=EGFR突变阳性非小细胞肺癌耐药后精准治疗, objectType=article, longId=92666, objectId=34fd926666c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34fd926666c, replyNumber=0, likeNumber=60, createdTime=2017-09-26, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34fd926666c, moduleTitle=EGFR突变阳性非小细胞肺癌耐药后精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34fd926666c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045838, encodeId=44f420458380d, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=2017 多机构治疗建议：复发淋巴结阳性非小细胞肺癌1期疾病立体定向放射治疗后再照射治疗, objectType=article, longId=106865, objectId=ef6e106865dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef6e106865dd, replyNumber=0, likeNumber=67, createdTime=2018-05-05, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef6e106865dd, moduleTitle=2017 多机构治疗建议：复发淋巴结阳性非小细胞肺癌1期疾病立体定向放射治疗后再照射治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef6e106865dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045836, encodeId=ed4a2045836a3, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, objectType=article, longId=101153, objectId=1b50101153e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b50101153e0, replyNumber=0, likeNumber=57, createdTime=2017-11-16, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b50101153e0, moduleTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b50101153e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045833, encodeId=b7712045833ad, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼, objectType=article, longId=98487, objectId=f82a9848ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f82a9848ea1, replyNumber=0, likeNumber=65, createdTime=2018-03-18, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f82a9848ea1, moduleTitle=Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f82a9848ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045837, encodeId=433f204583e51, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者, objectType=article, longId=101275, objectId=d71d1012e5ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71d1012e5ac, replyNumber=0, likeNumber=124, createdTime=2017-11-21, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71d1012e5ac, moduleTitle=Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71d1012e5ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045826, encodeId=a4e32045826bf, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=2015中国表皮生长因子受体基因敏感性突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南发布, objectType=article, longId=77551, objectId=078de755107, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=078de755107, replyNumber=0, likeNumber=60, createdTime=2017-03-31, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=078de755107, moduleTitle=2015中国表皮生长因子受体基因敏感性突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=078de755107)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045828, encodeId=e1192045828e5, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, objectType=article, longId=79864, objectId=5769e986481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769e986481, replyNumber=0, likeNumber=49, createdTime=2017-04-06, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769e986481, moduleTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5769e986481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045829, encodeId=ee272045829bd, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布, objectType=article, longId=81116, objectId=25a48111657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25a48111657, replyNumber=0, likeNumber=40, createdTime=2017-03-23, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25a48111657, moduleTitle=2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25a48111657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045824, encodeId=664b204582412, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=76572, objectId=8bfbe657216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bfbe657216, replyNumber=0, likeNumber=60, createdTime=2016-10-14, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bfbe657216, moduleTitle=精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bfbe657216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045825, encodeId=4ca9204582566, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, objectType=article, longId=77041, objectId=3754e70412b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3754e70412b, replyNumber=0, likeNumber=61, createdTime=2017-06-24, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3754e70412b, moduleTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3754e70412b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045831, encodeId=1a7c20458316f, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=88246, objectId=abae8824611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abae8824611, replyNumber=0, likeNumber=47, createdTime=2017-11-18, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abae8824611, moduleTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abae8824611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045830, encodeId=243d204583051, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=85252, objectId=aeb08525282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb08525282, replyNumber=0, likeNumber=76, createdTime=2017-05-31, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb08525282, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb08525282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045827, encodeId=7f84204582ea9, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, objectType=article, longId=79695, objectId=2555e969519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2555e969519, replyNumber=0, likeNumber=77, createdTime=2017-01-02, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2555e969519, moduleTitle=NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2555e969519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045823, encodeId=37b3204582325, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物, objectType=article, longId=65871, objectId=541e658e142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541e658e142, replyNumber=0, likeNumber=61, createdTime=2017-02-24, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541e658e142, moduleTitle=JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541e658e142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045822, encodeId=02452045822a2, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌, objectType=article, longId=64856, objectId=125f6485664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125f6485664, replyNumber=0, likeNumber=73, createdTime=2017-02-17, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125f6485664, moduleTitle=生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125f6485664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045821, encodeId=4c9f20458214a, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=ESMO 2014：克唑替尼可有效抑制ROS1阳性非小细胞肺癌的进展, objectType=article, longId=41397, objectId=a5934139eb6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5934139eb6, replyNumber=0, likeNumber=65, createdTime=2015-08-03, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5934139eb6, moduleTitle=ESMO 2014：克唑替尼可有效抑制ROS1阳性非小细胞肺癌的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5934139eb6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045820, encodeId=86a620458206e, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=中国表皮生长因子受体基因突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2013版), objectType=article, longId=30242, objectId=e02930242df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e02930242df, replyNumber=0, likeNumber=54, createdTime=2015-01-14, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e02930242df, moduleTitle=中国表皮生长因子受体基因突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2013版), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e02930242df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045819, encodeId=14d62045819be, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌, objectType=article, longId=25138, objectId=454325138e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=454325138e0, replyNumber=0, likeNumber=64, createdTime=2013-12-04, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454325138e0, moduleTitle=NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454325138e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阳性非小细胞肺癌

2020-05-29

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹

2017-09-25

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌

2018-04-23

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

EGFR突变阳性非小细胞肺癌耐药后精准治疗

2017-09-26

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

2017 多机构治疗建议：复发淋巴结阳性非小细胞肺癌1期疾病立体定向放射治疗后再照射治疗

2018-05-05

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！

2017-11-16

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼

2018-03-18

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者

2017-11-21

一叶知秋 (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

2015中国表皮生长因子受体基因敏感性突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南发布

2017-03-31

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS

2017-04-06

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布

2017-03-23

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）

2016-10-14

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格

2017-06-24

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2017-11-18

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2017-05-31

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NEJM：Pembrolizumab治疗PD-L1阳性非小细胞肺癌，疗效十分显著

2017-01-02

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物

2017-02-24

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌

2017-02-17

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

ESMO 2014：克唑替尼可有效抑制ROS1阳性非小细胞肺癌的进展

2015-08-03

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

中国表皮生长因子受体基因突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2013版)

2015-01-14

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NICE最终指导方案仍不推荐Xalkori用于治疗ALK阳性非小细胞肺癌

2013-12-04

科室
- - 订阅+
  - 更多科室
工具
服务